7-Aug-2026
TipRanks (Fri, 7-Aug 8:31 AM ET)
Morgan Stanley Reaffirms Their Buy Rating on Charles River Labs (CRL)
TipRanks (Fri, 7-Aug 8:30 AM ET)
Charles River Labs (CRL) Receives a Buy from Deutsche Bank
TipRanks (Thu, 6-Aug 9:18 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Charles River Labs (CRL), Zymeworks (ZYME)
TipRanks (Wed, 5-Aug 1:20 PM ET)
Charles River jumps on Q2 beats, guidance
Seeking Alpha News (Wed, 5-Aug 10:42 AM ET)
Market Chameleon (Wed, 5-Aug 5:47 AM ET)
Charles River Laboratories Non-GAAP EPS of $3.02 beats by $0.29, revenue of $1B beats by $22.8M
Seeking Alpha News (Wed, 5-Aug 7:15 AM ET)
Charles River Laboratories Announces Second-Quarter 2026 Results
Business Wire (Wed, 5-Aug 7:00 AM ET)
Charles River Laboratories Q2 2026 Earnings Preview
Seeking Alpha News (Tue, 4-Aug 11:55 AM ET)
Charles River Laboratories Schedules Second-Quarter 2026 Earnings Release and Conference Call
Business Wire (Wed, 15-Jul 8:00 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of August 7, 2026, CRL stock price climbed to $267.49 with 589,384 million shares trading.
CRL has a beta of 1.73, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.15 to the broad based SPY ETF.
CRL has a market cap of $13.68 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $1 billion in Revenue and $3.02 earnings per share. This beat revenue expectation by $31 million and exceeded earnings estimates by $.29.
In the last 3 years, CRL traded as high as $275.00 and as low as $91.86.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VOO, RSP, VB, IVV.
CRL has outperformed the market in the last year with a price return of +78.6% while the SPY ETF gained +23.5%. CRL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +47.2% and +18.1%, respectively, while the SPY returned +6.0% and +4.6%, respectively.
CRL support price is $257.10 and resistance is $273.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL shares will trade within this expected range on the day.